Methylene Blue vs PT-141
Well Studied vs FDA Approved
monitor Mechanism-based · 51% Both Methylene Blue and PT-141 can raise blood pressure. Monitor BP regularly and consider adding cardiovascular support (cardarine, telmisartan, or similar).
Molecular Data
Methylene Blue PT-141
Weight 319.85 Da —
Half-life ~5-6 hours ~2.7 hours
Type Phenothiazine dye (C16H18ClN3S) Melanocortin receptor agonist
Key Benefits
Methylene Blue
01 Enhances mitochondrial respiration and ATP production by acting as an alternative electron carrier
02 Reduces mitochondrial reactive oxygen species generation
03 Supports memory consolidation and cognitive performance at low doses
04 Neuroprotective effects demonstrated in models of Alzheimer's, Parkinson's, and traumatic brain injury
05 Improves mitochondrial function in aging cells and tissues
06 FDA-approved treatment for acquired methemoglobinemia
07 Anti-inflammatory and antimicrobial properties
PT-141
01 FDA-approved pharmaceutical route
02 Predictable absorption profile
03 Effective for both male and female sexual dysfunction
04 Works within 45 minutes
05 Effective in PDE5 inhibitor-resistant cases
06 Central mechanism (not dependent on blood flow)
Dosing Protocols
Methylene Blue
0.5-2 mg/kg oral (low-dose nootropic) / Once daily
PT-141
Women: 1.75mg (FDA-approved); Men: 1-2mg; Start 0.5mg test dose for tolerance / As needed before sexual activity; max 1 dose per 24 hours
Female HSDD (FDA-approved) 1.75mg As needed, max 1 dose/24hr
Male Erectile Dysfunction 1-2mg As needed, 45-60min before activity
Female Arousal Disorder 0.75-1.25mg As needed, max 1 dose/24hr
Low Starting Dose 0.5mg Test dose for tolerance assessment
Side Effects
Methylene Blue
Blue or blue-green discoloration of urine (expected and harmless)
Blue-green staining of the tongue and mouth with liquid formulations
Mild nausea or stomach discomfort, especially at higher doses
Blue discoloration of stool
Mild headache during initial use
PT-141
Nausea (40%)
Flushing (20%)
Headache (11%)
Injection site reactions
Contraindications
Concurrent use of SSRIs, SNRIs, or MAO inhibitors (serotonin syndrome risk)
Glucose-6-phosphate dehydrogenase (G6PD) deficiency (risk of severe hemolytic anemia)
Renal insufficiency (methylene blue is primarily renally excreted)
Known hypersensitivity to methylene blue or phenothiazine compounds
Pregnancy and breastfeeding (insufficient safety data)
Uncontrolled hypertension
Cardiovascular disease
Use of nitrate medications
Pregnancy or breastfeeding
Research Evidence
Methylene Blue PT-141
Status Well Studied FDA Approved
References 5 studies 4 studies
Latest 2017 2022
FDA Approved Yes Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.